Phase 3 FINESSE Trial Launches to Evaluate Finasteride in Prostate Cancer Active Surveillance
• A new Phase 3 trial called FINESSE will evaluate whether finasteride can improve adherence to active surveillance in men with low and intermediate-risk prostate cancer.
• The study will enroll 550 men across eight sites, randomizing patients to receive either standard active surveillance alone or with daily finasteride for two years.
• The trial aims to address poor long-term compliance with active surveillance, with outcomes tracked for up to 10 years including disease progression, mortality, and quality of life measures.
King's College Hospital to Pilot Ondine Biomedical's Steriwave for HAI Prevention
• King's College Hospital will pilot Ondine Biomedical's Steriwave technology as part of a quality improvement initiative to prevent hospital-acquired infections (HAIs).
• Steriwave uses a light-activated agent to eliminate infection-causing pathogens in a rapid, five-minute treatment, offering an alternative to antibiotics.
• Mid Yorkshire Teaching NHS Trust adopted Steriwave as standard of care for preventing surgical site infections in hip and knee surgery patients in March 2024.
• Steriwave's accessibility has increased across England and Wales after its addition to the NHS Supply Chain in June 2024, facilitating broader adoption.
© Copyright 2025. All Rights Reserved by MedPath